"We know that based on progression-free survival , there is no way the drug will get approval anywhere in the world," Chief Executive Jonathan Lewis said, according to Reuters This shocking move sent Ziopharm down by nearly 65% in Tuesday's trading, which moved the valuation of the company to about $145 million, or a price per share of $1.82 at ... (more)
http://seekingalpha.com/article/1306111-ziopharm-s-palifosfamide-fails-its-soft-tissue-cancer-indication-nsclc-next?source=feed
http://seekingalpha.com/article/1306111-ziopharm-s-palifosfamide-fails-its-soft-tissue-cancer-indication-nsclc-next?source=feed
No comments:
Post a Comment